Description

Fraxiparin Solution for Injections Syringe 0.6 ml. №10

Ingredients:

Fraxiparin contains enoxaparin sodium, which is a low molecular weight heparin.

Dosage:

The recommended dosage of Fraxiparin is determined based on the patient’s weight, medical condition, and the indication for use. It is administered subcutaneously.

Indications:

Fraxiparin is indicated for the prevention of deep vein thrombosis (DVT) in patients undergoing surgery and for the treatment of DVT and pulmonary embolism.

Contraindications:

Fraxiparin is contraindicated in patients with a history of heparin-induced thrombocytopenia, active major bleeding, or hypersensitivity to enoxaparin or heparin.

Directions:

Administer Fraxiparin subcutaneously in the abdomen, alternating sides. Do not expel the air bubble from the syringe before injection.

Scientific Evidence:

Studies have shown that enoxaparin, the active ingredient in Fraxiparin, effectively prevents and treats thromboembolic disorders. Research published in the New England Journal of Medicine demonstrated the efficacy of enoxaparin in reducing the risk of venous thromboembolism in surgical patients.

Additional Information:

It is important to monitor platelet counts regularly during treatment with Fraxiparin to detect any signs of thrombocytopenia. Inform healthcare providers about any concurrent medications to avoid potential drug interactions.

Fraxiparin exerts its pharmacological effects by enhancing the inhibition of factor Xa and thrombin, key enzymes in the coagulation cascade. This leads to the prevention of blood clot formation and reduces the risk of thromboembolic events.

Clinical trials have compared the effectiveness of enoxaparin with other anticoagulants, showing similar efficacy in preventing deep vein thrombosis postoperatively. The convenience of a pre-filled syringe formulation like Fraxiparin can improve patient compliance and dosing accuracy.